Vera Therapeutics (VERA) Free Cash Flow (2020 - 2026)
Vera Therapeutics (VERA) reported Free Cash Flow of -$106.5 million for Q1 2026, down 95.12% on a YoY basis from -$2.2 billion in Q1 2025, and down 51.97% quarter-over-quarter from -$70.1 million in Q4 2025.
Vera Therapeutics (VERA) Free Cash Flow (2020 - 2026) Analysis & Trends
Vera Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$106.5 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 95.12% year-over-year to -$106.5 million; the trailing twelve-month figure through Mar 2026 stood at -$293.7 million (down 87.75% YoY), and the FY2025 full-year result was -$241.7 million, down 78.2% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$106.5 million, down from -$70.1 million in the prior quarter.
- The five-year high for Free Cash Flow was -$9.0 million in Q1 2022, with the low at -$106.5 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$37.9 million across 5 years, with a median of -$26.3 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 236.58% — and 2023, when it gained 6.65%.
- Vera Therapeutics' Free Cash Flow stood at -$21.2 million in 2022, then decreased by 19.11% to -$25.2 million in 2023, then slumped by 58.0% to -$39.8 million in 2024, then plunged by 76.0% to -$70.1 million in 2025, then plunged by 51.97% to -$106.5 million in 2026.
- The last three Free Cash Flow figures came in at -$106.5 million (Q1 2026), -$70.1 million (Q4 2025), and -$62.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Vera Therapeutics | 2.51 Bn | 1.91 Bn | - | -106.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -106.52 Mn |
| Mar 31, 2026 | -106.52 Mn |
| Dec 31, 2025 | -70.10 Mn |
| Dec 31, 2025 | -70.10 Mn |
| Sep 30, 2025 | -62.04 Mn |
| Sep 30, 2025 | -62.04 Mn |
| Jun 30, 2025 | -55.01 Mn |
| Jun 30, 2025 | -55.01 Mn |
| Mar 31, 2025 | -54.59 Mn |
| Mar 31, 2025 | -54.59 Mn |
| Dec 31, 2024 | -39.83 Mn |
| Dec 31, 2024 | -39.83 Mn |
| Sep 30, 2024 | -37.12 Mn |
| Sep 30, 2024 | -37.12 Mn |
| Jun 30, 2024 | -24.87 Mn |
| Jun 30, 2024 | -24.87 Mn |
| Mar 31, 2024 | -33.83 Mn |
| Mar 31, 2024 | -33.83 Mn |
| Dec 31, 2023 | -25.21 Mn |
| Dec 31, 2023 | -25.21 Mn |